Concepedia

Ryan M. Esquejo

RM

Statistics

Publications

10

Citations

1.4K

H-Index

10

Active since

2013

Affiliations

Pfizer (United States)(Current)

Sanford Burnham Prebys Medical Discovery Institute

Discovery Institute

Pfizer (United Kingdom)

Inserm

Ryan M. Esquejo is an author at Pfizer (United States) specializing in life sciences, lipid metabolism, and pharmacology.

ORCID

Publications per year

2013–2022

10

Publications

10

Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis

Ji Miao, Alisha V. Ling, Praveen V. Manthena et al. · Nature Communications · 2015 · 370 citations · Full text

, , +15

Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice

Emily Cokorinos, Jake Delmore, Allan R. Reyes et al. · Cell Metabolism · 2017 · 266 citations · Full text

, , +13

GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates

Danna M. Breen, Hanna Kim, Donald Bennett et al. · Cell Metabolism · 2020 · 178 citations

, , +14

Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models

Ryan M. Esquejo, Christopher T. Salatto, Jake Delmore et al. · EBioMedicine · 2018 · 150 citations · Full text

, , +17

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Aditi R. Saxena, Donal Gorman, Ryan M. Esquejo et al. · Nature Medicine · 2021 · 142 citations

, , +10

1–5 of 10